A multinational consortium led by the Garvan Institute of Medical Research has introduced AAnet, an advanced AI-driven framework designed to delineate cellular heterogeneity within tumors with unprecedented resolution. This technology addresses challenges in treating heterogeneous cancers like triple-negative breast cancer by enabling personalized therapies targeting diverse cell populations. Parallel advancements include a new AI platform, PromoterAI by Illumina, which accurately identifies disease-driving promoter mutations implicated in genetic disorders and cancers, as published in Science. Enhancing genomic insights further, Enhanced Genomics has partnered with the Alborada Drug Discovery Institute to leverage 3D multiomics and promoter capture Hi-C technology for Alzheimer's target discovery, reflecting a rising trend in AI-powered precision medicine.